Safety, Pharmacokinetics, and Pharmacodynamics of TD‐0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects

TD‐0714 is an orally active, potent, and selective inhibitor of human neprilysin (NEP) in development for the treatment of chronic heart failure. Oral administration of TD‐0714 in rats resulted in dose‐dependent and sustained increases in plasma cyclic guanosine monophosphate (cGMP) over 24 hours co...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanodia, Jitendra, Lo, Arthur, Baldwin, R. Michael, Colley, Ken, Zhou, Kefei, Bourdet, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719375/
https://www.ncbi.nlm.nih.gov/pubmed/32506827
http://dx.doi.org/10.1111/cts.12831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719375/
https://www.ncbi.nlm.nih.gov/pubmed/32506827
http://dx.doi.org/10.1111/cts.12831

Ejemplares similares